Walleye Capital’s West Pharmaceutical WST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-3,600
Closed -$788K 5220
2025
Q2
$788K Buy
3,600
+2,900
+414% +$620K ﹤0.01% 2244
2025
Q1
$157K Sell
700
-700
-50% -$193K ﹤0.01% 3417
2024
Q4
$459K Buy
1,400
+400
+40% +$126K ﹤0.01% 3060
2024
Q3
$300K Sell
1,000
-2,200
-69% -$674K ﹤0.01% 3723
2024
Q2
$1.05M Buy
3,200
+2,000
+167% +$707K ﹤0.01% 2796
2024
Q1
$475K Sell
1,200
-800
-40% -$296K ﹤0.01% 3244
2023
Q4
$704K Sell
2,000
-2,100
-51% -$743K ﹤0.01% 2665
2023
Q3
$1.54M Buy
+4,100
New +$1.59M ﹤0.01% 1927

Other funds holding WST

Walleye Capital's WST Position: Q1 2026 in Review

Walleye Capital sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 134,453 shares — an estimated $37M sold.

Walleye Capital first reported a position in WST in Q2 2022 and held it in 12 quarters. The position peaked at $37M in Q4 2025. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Walleye Capital reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 134,453 West Pharmaceutical shares in Q1 2026, an estimated $37M.
  • Walleye Capital first reported a position in West Pharmaceutical in Q2 2022 and held it in 12 quarters.
  • Walleye Capital's West Pharmaceutical position peaked at $37M in Q4 2025.
  • 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.